North America Coagulation Market
Published On: Mar 2024
Published On: Mar 2024
At 6.9% CAGR, the North America Coagulation Market is Projected to be Worth US$ 4,633.26 Million by 2030, Says Business Market Insights
According to Business Market Insights research, the North America coagulation market was valued at US$ 2,712.64 million in 2022 and is expected to reach US$ 4,633.26 million by 2030, registering a CAGR of 6.9% from 2022 to 2030. Development of point-of-care (POC) coagulation analyzers and increasing prevalence of blood disorders are among the critical factors attributed to the North America coagulation market expansion.
A rapid, reliable assessment of hemostasis is essential for patients suffering from trauma or other bleeding problems. Due to the constraints of sample preparation and analytical process, routine coagulation assays cannot analyze clot formation, and their results can be obtained only after 30-90 minutes. POC devices such as platelet function test, viscoelastic coagulation tests, blood gas analysis, and other coagulometers are available for assessment of hemostasis. A POC measurement tool can be used inside and outside the hospital as a decision-making and management tool. When time is paramount, POC analyzers provide immediate, actionable results in emergency rooms, coronary care units, surgery, and procedure suites. In addition to outpatient clinics and physicians' offices, these devices can assist in patient management in pharmacies, care centers, and patients' homes. POC coagulation analyzers offer timely results without compromising diagnostic quality control provided by central labs. In POC testing, it is important to provide fast results, along with accuracy and quality assurance.
In 2021, Siemens Healthineers launched fully automated CN-3000 and CN-6000 systems, which are mid- and high-volume handheld POC coagulation testing devices. The FDA cleared Siemens Healthineers' Xprecia Stride Coagulation Analyser in 2016, as a POC coagulation analyzer device. The device has demonstrated prothrombin time/international normalized ratio (PT/INR) testing performance equivalence to Roche CoaguChek XS.
Thus, the growing developments in POC coagulation analyzers are expected to boost the coagulation market growth during the forecast period.
On the contrary, high costs associated with coagulation analyzers hampers the growth North America coagulation market.
Based on disease indication, the North America coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held 54.0% share of the North America coagulation market in 2022, amassing US$ 1,464.05 million. It is projected to garner US$ 2,493.22 million by 2030 to expand at 6.9% CAGR during 2022-2030.
Based on type, the North America coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held 66.7% share of the North America coagulation market in 2022, amassing US$ 1,808.71 million. It is projected to garner US$ 2,937.27 million by 2030 to expand at 6.2% CAGR during 2022-2030. Clinical laboratory analysers is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.
In terms of offering, the North America coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held 64.5% share of the North America coagulation market in 2022, amassing US$ 1,748.38 million. It is projected to garner US$ 2,971.43 million by 2030 to expand at 6.9% CAGR during 2022-2030. Diagnosis is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.
By technology, the North America coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held 59.3% share of North America coagulation market in 2022, amassing US$ 1,608.88 million. It is projected to garner US$ 2,782.91 million by 2030 to expand at 7.1% CAGR during 2022-2030.
By end user, the North America coagulation market is segmented into clinical laboratories, hospitals, and others. The clinical laboratories segment held 60.2% share of North America coagulation market in 2022, amassing US$ 1,634.17 million. It is projected to garner US$ 2,831.83 million by 2030 to expand at 7.1% CAGR during 2022-2030.
Based on country, the North America coagulation market is categorized into the US, Canada, and Mexico. The US held 84.1% share of North America coagulation market in 2022, amassing US$ 2,279.97 million. It is projected to garner US$ 3,846.07 million by 2030 to expand at 6.8% CAGR during 2022-2030.
Key players operating in the North America coagulation market are Diagnostica Stago Inc, F Hoffmann-La Roche Ltd, Genrui Biotech Co, Ltd, Helena Laboratories Corporation, Horiba Ltd, ImproGen Diagnostik Kimya San. & Tic. Ltd ?ti, Siemens Healthineers AG, Sysmex Corp, and Transasia Bio-Medicals Ltd, among others.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
